Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aslan Pharmaceuticals Ltd ADR (ASLN)

Aslan Pharmaceuticals Ltd ADR (ASLN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aslan Pharmaceuticals Ltd ADR 83 CLEMENCEAU AVENUE NO 12-03 UE SQUARE SINGAPORE U0 239920 SGP

P: 65-6222-4235 F: +65 62252419

Description:

ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore.

Key Statistics

Overview:

Market Capitalization, $K 50,914
Enterprise Value, $K -8,396
Shares Outstanding, K 69,745
Annual Sales, $ 0 K
Annual Net Income, $ -31,320 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -10,930 K
60-Month Beta 1.64
% of Insider Shareholders 4.69%
% of Institutional Shareholders 31.59%
Float, K 66,474
% Float 95.31%
Short Volume Ratio 0.60

Growth:

1-Year Return -17.93%
3-Year Return -63.50%
5-Year Return 0.00%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.16 on 10/28/22
Next Earnings Date 11/01/22
Earnings Per Share ttm -0.54
EPS Growth vs. Prev Qtr 15.79%
EPS Growth vs. Prev Year -33.33%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ASLN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -117.21%
Return-on-Assets % -54.38%
Profit Margin % 0.00
Net Margin % N/A
Debt/Equity 1.65
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.37
Book Value/Share 0.00
Interest Coverage -15.98
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar